Trending Topic

3D Rendered Medical Illustration of Male Anatomy - Colon Cancer; Ascending Colon.
17 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Rat sarcoma virus (RAS) proteins are a family of prototypical oncogenes frequently mutated in human cancers. Mutations in the RAS gene account for 19% of all pathogenic alterations and are the subject of extensive research in molecular and clinical oncology.1 The RAS family consists of three major isoforms, namely the Harvey rat sarcoma virus (HRAS), the neuroblastoma RAS […]

Shaji Kumar, ASCO20: Efficacy and Toxicity in the Randomised Phase III ENDURANCE Trial in Myeloma

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 8th 2020

We are joined by touchONCOLOGY’s Oncology & Hematology Review (US) Editor-in-Chief Shaji Kumar, Mayo Clinic, to discuss his plenary session at ASCO20 on the efficacy and toxicity in the randomized phase III ENDURANCE trial of the use of bortezomib, lenalidomide and dexamethasone for initial therapy of newly diagnosed multiple myeloma.

Questions

1. What is the rationale for the use of bortezomib, lenalidomide and dexamethasone for initial therapy of newly diagnosed multiple myeloma, and what are the limitations of this regime? (0:06)

2. What were the aims and design of the ENDURANCE trial? (1:38)

3. What were the major efficacy findings of this trial? (3:12)

4. What was the safety profile of this combination and what were the findings in terms of cardiovascular events? (4:34)

5. Despite these promising findings, multiple myeloma remains incurable. What future strategies are likely to further improve outcomes in the coming years? (5:56)

 

Speaker disclosure: Shaji Kumar has received research funding for clinical trials to the institution from Celgene, Takeda, Janssen, BMS, KITE, Merck, Abbvie, Medimmune, Novartis, Roche-Genentech, Amgen, Tenebio and Carsgen. He has received consulting/advisory board participation fees to his institution from Celgene, Takeda, Janssen, Abbvie, Genentech, Amgen, Molecular Partners and (with personal payment) Oncopeptides, Genecentrix and Cellectar.

Support: Interview and filming supported by Touch Medical Media.

Filmed in coverage of the 2020 ASCO Virtual Scientific Program.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup